Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | SGNTUC-019: tucatinib + trastuzumab for previously treated HER2+ metastatic biliary tract cancer

Yoshiaki Nakamura, MD, PhD, from the National Cancer Center Hospital East, Kashiwa, Japan, discusses the significance of the tucatinib and trastuzumab combination as a chemotherapy-free treatment option for HER2-positive metastatic biliary tract cancer (BTC). Dr Nakamura highlights how previous treatment options offered limited benefits, with modest response rates and short overall-survival (OS). The results of the Phase II SGNTUC-019 trial (NCT04579380) evaluating the combination of tucatinib and trastuzumab demonstrated superior efficacy compared to historical controls, emphasizing the importance of targeted therapy over chemotherapy for patients with HER2-positive metastatic BTC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.